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Objective: The objective of this study was to demonstrate a technique that uses physician-assembled endografts to make
use of the beneﬁts of parallel grafts while also providing for circumferential seal and ﬁxation in repair of thor-
acoabdominal aneurysms in inoperable patients.
Methods: A single-center all-comers retrospective analysis of 14 patients was performed that looked at the early outcomes
of patients treated for thoracoabdominal aneurysms. Three Crawford type II, four type III, four type IV, and three type V
thoracoabdominal aneurysms were treated. Contrast material, ﬂuoroscopy time, length of stay, clinical success, and
technical success were measured.
Results: There was no in-hospital, 30-day, or 6-month mortality. We found two type III endoleaks in the early design.
One required coil embolization. Average volume of contrast material and average ﬂuoroscopy time were 76.9 mL and
119.1 minutes, respectively. Average length of stay was 10.5 days, and average procedure time was 251.2 minutes.
Clinical success was observed in 78.6% of patients to date, and technical success was observed in 85.7% of patients.
Conclusions: Short-term results show that this approach is safe. The device can be safely implanted, is off-the-shelf, and
can treat each of the Crawford thoracoabdominal aneurysm types. Finally, the assembly of off-the-shelf components may
shorten the regulatory path for this physician-assembled endograft. (J Vasc Surg 2014;60:1177-85.)Open repair of thoracoabdominal aortic aneurysms
(TAAAs), especially in patients with pre-existing comorbid-
ities, is fraught with complications. A meta-analysis of 7833
open repairs of TAAAs from 2000 to 2010 found a 30-day
mortality rate of 7%, in-hospital mortality rate of 10%, spi-
nal cord ischemia rate of 7.5%, renal failure rate of 19%, and
pulmonary dysfunction rate of 36%.1 Predictors of adverse
events after elective open repair based on pre-existing
comorbidities have been established. Advanced age
(>70 years),2-5 respiratory disease,4 renal insufﬁciency,6
coronary artery disease,2,5 symptomatic aneurysms, extent
I and II aneurysms,7-10 and diabetes11 are reported to be
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The outcomes reported are in a low- to moderate-risk
patient population. It is a logical extension to assume that
the outcomes in moderate- to high-risk patients would be
worse, so patients deemed to be at moderate to high risk
on the basis of pre-existing comorbidities or emergent sta-
tus need an off-the-shelf technique for endovascular repair.
Whereas good results have been achieved with branched
and fenestrated devices, the custom build and manufacture
lead times limit the availability, so these devices are not
available for all patients with emergent status. Two clever
sandwich techniques have been proposed to care for pa-
tients with an off-the-shelf approach. The ﬁrst used dual
bifurcated infrarenal grafts in the descending thoracic
aorta.16 The second used three or four bridging stents
sandwiched with a thoracic graft in the descending thoracic
aorta.17 Although these sandwich techniques can be used
off-the-shelf, they do not provide for circumferential seal
and ﬁxation, and long-term durability is in question.
Here we propose a technique that requires only one
measurement for the main body grafts: the proximal seal
zone diameter. It also provides for circumferential seal
and ﬁxation at the seal zone and each of the modular junc-
tions in the assembly while still making use of the advan-
tages of parallel grafts. In the period during which these
14 patients were treated, the closest investigational site
for the Cook t-Branch was roughly 1000 miles away
from our center. The travel required for that investigational
device is not realistic. Because of this, several of the patients
were not candidates. Of our 14 patients, none were candi-
dates for a custom fenestrated device because none of them1177
Fig 1. Sequence of constructing (A) the thoracic bifurcation graft (early conﬁguration shown in B), including
(C) sewing the common seam and (D) sewing the end-to-end anastomosis between the Valiant and the two Endurant
limbs. E, Top view of the thoracic bifurcation showing no gutters.
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ﬁrst patient had been observed for 9 months and the sec-
ond patient had been observed for 3 months, we decided
to begin offering this treatment more widely and to begin
pursuing a sponsor-investigator investigational device
exemption that will allow us to collect prospective data of
both elective and symptomatic patients treated with this
physician-assembled endograft (PAEG).
METHODS
Physician-assembled stent grafts. Two custom grafts
were assembled for this procedure. The ﬁrst stent graft,
referred to as the thoracic bifurcation (Fig 1, A) stent
graft, was originally made with a vertical seam spanning half
the length of the Valiant, dividing the distal end into two
lumens (Fig 1, B). After the second patient, the design was
modiﬁed and consisted of a Valiant straight thoracic graft
(Medtronic Endurant, Minneapolis, Minn) size matched to
the thoracic aorta and shortened to approximately 50 mm
in length, a 20  82-mm iliac extender limb, and a 16 
82-mm iliac extender limb (Medtronic), which were both
eventually shortened to 50 mm as well. The iliac extenderlimbs were then sutured together, forming a common seam
(Fig 1, C). From here, the 20-mm iliac limb was slid onto
the Valiant deployment shaft. Approximately 2 cm of the
proximal end of the Valiant graft was deployed but con-
strained with 20-gauge surgical wire. The remaining graft
was then deployed and trimmed to approximately 50 mm
(Fig 1, D). Cut ends were heat sealed to avoid fraying. The
seam of the Valiant graft was salvaged, tied, and reinforced
with 5-0 Prolene sutures. The paired iliac extenders were
then sutured end to end to the shortened end of the
Valiant with 6-0 Prolene by a running locked stitch in such
a way that there were no gutters formed (Fig 1, E). The
thoracic bifurcation requires one Valiant and two Endurant
limbs. For ﬁnal seal, the thoracic bifurcation is extended
distally to either healthy infrarenal aorta in the case of a
Crawford type I or type V aneurysm or to the infrarenal
graft in all other Crawford types. Endurant extension limbs
are used for this purpose.
The second graft, referred to here as the visceral mani-
fold (Fig 2, A), was assembled from a modiﬁed 23  13 
82-mm Endurant stent graft (Medtronic) and four 7-mm
Viabahn stent grafts (W. L. Gore & Associates, Flagstaff,
Fig 2. Sequence of construction of (A) the visceral manifold, including (B) sewing a common seam between two
shortened Gore Viabahns and (C) sewing the Gore Viabahns to the distal end of a Medtronic Endurant in an end-
to-end anastomosis. D, Top view of the visceral manifold showing no gutters.
Fig 3. Spiral wire re-constraining technique.
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0 Prolene, forming a common seam (Fig 2, B). One pair
of Viabahn stent grafts was slid over the Endurant deploy-
ment shaft. The Endurant graft was wrapped in 20-gauge
surgical wire as it was deployed to keep the proximal graft
constrained. After the remaining graft was deployed, the
ipsilateral limb was shortened by 1 cm shorter than the
contralateral limb. One pair of 7-mm Viabahn covered
stent grafts were joined to each limb of the Endurant graft
with 5-0 Prolene sutures, end to end, with a running
locked stitch (Fig 2, C) so no gutters were formed
(Fig 2, D). The Viabahns were shortened to 3 cm once su-
turing was complete. The visceral manifold requires one
Endurant bifurcated graft and four Gore Viabahns. The
visceral manifold requires two or three iCAST stent grafts
and one Protégé stent per limb to extend to each of the
visceral vessels.In both of these constructs, the grafts were fully con-
strained by wrapping with 20-gauge surgical wire (Fig 3).
To resheath the constructs, the wire was unwound as the
outer sheath was readvanced over the newly constructed
Fig 4. A,Demonstration of early concept including an animation of the assembly in a type III thoracoabdominal aortic
aneurysm (TAAA). B, Top view of a three-dimensional printed type III TAAA with 4 L/min water ﬂowing to simulate
in vivo use. C, Stents in the visceral vessels after simulated use. D, Assembly of all component devices as they would be
deployed in vivo.
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Simulated use. The PAEGs were constructed and
deployed within a three-dimensional printed type III
TAAA with water ﬂowing through the aorta to simulate
blood ﬂow (Fig 4, A-C). With this model, the procedural
details could be optimized, and veriﬁcation of graft-to-graft
ﬁxation in the presence of downward force from ﬂuid ﬂow
through the bifurcations could be obtained. The grafts
from the procedure were removed from the model
(Fig 4, D). They were then imaged with a scanning elec-
tron microscope to determine whether there was any
damage to the stents, cover, or sutures.
Study design. This study consists of a retrospective re-
view of 14 patients who have been treated for elective or
symptomatic TAAAs from March 2012 to the present
with the endovascular debranching technique. Various
perioperative statistics were gathered from the chart,
including estimated blood loss, operating room time, vol-
ume of contrast material used, ﬂuoroscopy time, number
of visceral arteries stented, and length of hospital stay. Pa-
tients were also observed at postoperative week 1 and at
1 month, 6 months, and 1 year. At the follow-up, pa-
tients were monitored for endoleak, stent graft migration,
and aneurysm sac growth. From this information, we
measured both technical success (successful delivery,
deployment, and patency of all endovascular graft com-
ponents) and clinical success (technical success and
freedom from aneurysm enlargement, freedom from
aneurysm rupture, freedom from conversion to openrepair, freedom from secondary intervention for type I and
type III endoleak, freedom from device integrity failure,
and freedom from patency-related events). Early on, pa-
tients with previously placed infrarenal stent grafts with
suprarenal ﬁxation were treated, but later in the series,
those patients were excluded.
All of the patients who underwent this procedure were
clearly informed that the devices would be used outside of
their Food and Drug Administration (FDA)elabeled indi-
cations. The speciﬁc modiﬁcations that would be used were
described, and the patients were told that long-term dura-
bility and safety have not been proved; the risks and bene-
ﬁts of open repair as well as the risks and beneﬁts of electing
no treatment were explained. The patients were also
informed of regional centers that offered FDA investiga-
tional devices for the treatment of TAAA.
On December 12, 2012, the Sanford Research Institu-
tional Review Board gave approval for patient data to be
collected retrospectively and then saved in a database. On
June 4, 2013, that application to the Institutional Review
Board was amended so that the patients could consent
again for their information to be shared with scientiﬁc jour-
nals as well as with the FDA.
Patient selection. Patient characteristics are presented
in Table I. The mean age of patients was 73.2 years (range,
61-87 years). Three patients were classiﬁed as American
Society of Anesthesiologists risk class 4 and 11 were classi-
ﬁed as risk class 3. High-risk patients with comorbidities
prohibitive for open surgery were considered candidates for
total endovascular aneurysm repair (EVAR). These
Table I. Patient characteristics
No. (%)
Coronary artery disease 4 (28.6)
Previous myocardial infarction 2 (14.3)
Congestive heart failure 2 (14.3)
Previous coronary artery bypass graft 4 (28.6)
Previous PTCA 2 (14.3)
Previous aortic surgery 5 (35.7)
Previous abdominal surgery 1 (7.14)
Ejection fraction <50% 3 (21.4)
Hypertension 13 (92.9)
Hyperlipidemia 10 (71.4)
Smoking 14 (100)
Active smoker 4 (28.6)
Chronic obstructive pulmonary disease 9 (64.3)
Home oxygen/steroids 7 (50)
Diabetes mellitus 4 (28.6)
Renal insufﬁciency 3 (21.4)
Terminal renal insufﬁciency 11 (78.6)
Hostile abdomen 5 (35.7)
Peripheral artery disease 5 (35.7)
Previous coronary vascular accident 3 (21.4)
PTCA, Percutaneous transluminal coronary angioplasty.
Table II. Aneurysm characteristics and type of repair
No. (%)
Patients 14
Symptomatic 3 (21.4)
Aneurysm type
Pararenal 0 (0)
Crawford type I 0 (0)
Crawford type II 3 (21.4)
Crawford type III 4 (28.6)
Crawford type IV 4 (28.6)
Crawford type V 3 (21.4)
Devices used
Medtronic Valiant 1
Medtronic Endurant limb 3.8
Medtronic Endurant bifurcated graft 1.8
Gore cuff 0.79
Gore Viabahn 4
Atrium iCAST 8
eV3 Protégé 4
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tion (<50%), severe pulmonary dysfunction (forced expi-
ratory volume in 1 second <1 L), hostile anatomy from
multiple prior abdominal surgeries, and diabetes mellitus
(medication and diet controlled). Of the 14 patients treated
with this technique, four (28.6%) had coronary artery dis-
ease, ﬁve (35.7%) had prior aortic surgery, nine (64.3%) had
chronic obstructive pulmonary disease, four (28.6%) had
diabetes mellitus, three (21.4%) had renal insufﬁciency, ﬁve
(35.7%) had peripheral artery disease, ﬁve (35.7%) had a
hostile abdomen, and three (21.4%) were symptomatic.
There were three Crawford type II aneurysms, four
type III aneurysms, four type IV aneurysms, and three
type V aneurysms. The average diameter of the aneurysms
treated was 6.2 cm as measured in the long axis (Table II).
Intervention. The graft assembly procedure was car-
ried out in the sterile ﬁeld while the patient was being pre-
pared for anesthesia. With the patient under general
anesthesia, a Swan-Ganz catheter (Edwards Lifesciences
Corp, Irvine, Calif) and lumbar drain were placed in 13 of
14 patients. After preparation and draping from the clavi-
cles to midthigh in normal sterile fashion, the right or left
axillary and bilateral common femoral arteries were
exposed; 10-mm Hemashield Dacron tube grafts (Atrium
Medical, Hudson, NH) were then sewn to the axillary and
either the right or left femoral arteries.
All access was made by needle, followed by wire, fol-
lowed by sheath. A marking pigtail catheter was placed
from the nonconduit femoral access; angiography was per-
formed, and measurements were taken. The thoracic bifur-
cation graft was positioned and deployed from the femoral
conduit so that its distal end landed 7 to 8 cm proximal to
the takeoff of the celiac artery. A wire was then placed in
the 16-mm lumen of the double barrel from the noncon-
duit femoral access, and a marking pigtail catheter was
placed. The visceral manifold was positioned in the20-mm limb and deployed. The manifold graft landed
such that the distal end of the manifold graft was approxi-
mately 2 to 3 cm superior to the celiac artery.
Once these grafts were properly positioned, our atten-
tion turned to the axillary conduit. An 8F sheath was
placed into the descending aorta and eventually into the
visceral manifold graft. From here, a wire was placed in a
distal Viabahn and extended to cannulate a renal artery.
Size-appropriate iCAST (Atrium, Hudson, NH) balloon-
expandable stent grafts were used to bridge the renal artery
to the visceral manifold. This was smoothed with an over-
sized self-expanding Protégé stent (ev3 Endovascular Inc,
Plymouth, Minn). This process was sequentially repeated
for the rest of the visceral segment.
Once each of the visceral vessels had been excluded,
the marking pigtail catheter in the 16-mm lumen was
exchanged for a stiff Meier wire. From here, we extended
the 16-mm lumen distally with a 16  (16 or 20) 
(154 or 199) Endurant limb stent graft (Medtronic).
This was extended to approximately 4 cm distal to the renal
arteries. From this point, we followed a traditional infrare-
nal EVAR with the Endurant II stent graft system (Med-
tronic), which had its suprarenal ﬁxation bars covered
with a Gore 2.3-  3.5-cm cuff (W. L. Gore & Associates).
The purpose of this cuff was to block any endoleak that
may result from a tear in the cloth of the descending
limb should the traumatic hooks of the suprarenal ﬁxated
graft penetrate the extension graft.
Standard heparinization practice was followed
throughout the procedure. The activated clotting time
(goal > 300 seconds) was rechecked every 30 minutes.
Overlaps of 5 cm were used between all major compo-
nents; 3.5-cm overlaps were used between bridging stents
and Viabahn limbs, and all contact points were balloon
angioplastied. Completion angiography was performed to
conﬁrm graft patency. Standard practice was followed in
closing arteriotomies and incision sites. The patients
remained intubated after the procedure and were
Table III. Perioperative statistics
Patient
Contrast
material, mL
Fluoroscopy
time, minutes
Arteries
stented
Estimated
blood loss, mL
Operative time,
minutes
Length of stay,
days
1a 90 124 3 900 302 4c
2 95 137 4 700 291 12c
3 75 71 4 450 182 3c
4 62 70 3 250 191 10
5 137 187 4 1200 362 15c
6a,b 43 140 2 700 300 13c
7a,b 63 238 3 1500 440 26
8 99 110 4 300 191 9c
9 66 82.5 4 500 181 4c
10 67 70 4 500 167 4c
11a 70 101 4 700 211 9c
12 55 126 3 500 244 21
13 67 96 4 800 196 9c
14a 97 144.3 4 1500 259 5c
aRequired femoral-femoral bypass because of unilateral iliac.
bPrevious infrarenal graft with suprarenal ﬁxation.
cDischarged to home.
Table IV. Follow-up schedule
Patient 1 week 1 month 6 months 12 months
1 X X X X
2 X X X X
3 X X X X
4 X X X X
5 X X X X
6a X X X X
7 X X X X
8 X X X
9 X X X
10 X X X
11 X X X
12a X X X
13 X X X
14 X X
aRequired dialysis postoperatively.
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phy (CT) scans were obtained in the ﬁrst 24 to 48 hours.
CT angiography (CTA) was performed with a helical
acquisition pattern and a thickness per interval of 2.5 mm.
RESULTS
Technical results. Aneurysm exclusion was achieved in
all patients, with 51 of 54 (94.4%) possible visceral vessels
being revascularized. Average ﬂuoroscopy time and volume
of contrast medium administered were 119.1 minutes
(range, 70-238 minutes) and 76.9 mL (range, 43-
137 mL). Average estimated blood loss was 750 mL
(250-1500 mL), and average operating room time was
251 minutes (167- 440 minutes). There was one patient
with a type III endoleak that resolved on its own, and
one patient with a type III endoleak that required reinter-
vention with coil embolization. Two additional patients
had a type II endoleak. Technical success was achieved in
85.7% of patients. Clinical success was observed in 78.6%
of patients to date. Average length of stay for these patients
was 10.5 (4-26) days (Table III). There was no in-hospital
mortality, one case of in-hospital paraplegia, and two cases
of permanent dialysis. All grafts have remained patent
throughout the follow-up period with no evidence of graft
migration or aneurysm sac growth (Table IV).
DISCUSSION
Placement of the thoracic bifurcation ﬂow-
compartmentalizing graft cephalad to the celiac artery
makes main body graft alignment less critical. To address
the type III endoleak that occurred in the ﬁrst two cases,
we needed to evaluate the early conﬁguration of the
thoracic bifurcation. We initially constructed this by sewing
a common vertical seam that ran for 5 cm on the distal end
of a 100-mm thoracic stent graft. This created two eye-
shaped lumens, thus creating gutters leading to type III
endoleaks. The ﬁrst patient’s endoleak needed to be coilembolized, but the second patient’s endoleak did resolve
on its own. At this point, we realized that we needed to
modify the design so that those lumens were round,
providing for circumferential seal and ﬁxation. That is
when we began stitching the 20-mm and 16-mm limb ex-
tensions onto the distal end of the thoracic graft so that the
lumens were round and encouraged good seal.
We have observed good patency rates in the renal
arteries as well as in the celiac and superior mesenteric
arteries. We think this may be because we take a 23-mm
main body and divide it into four freely moving 7-mm-
diameter limbs positioned for antegrade ﬂow, with much of
the ﬂowbeing derived from the central ﬂow streamof the aorta
vs the peripheral edge of the ﬂow stream, where laminar ﬂow is
essentially stationary. Placement of the visceral manifold 2 cm
or so above the celiac artery allows our endo-bypasses to follow
a relaxed path to each of the visceral branches. This allows a
more gradual sweep of the grafts and less restriction in ﬂow.
We believe that this is what has led to 51 of 51 vessels remain-
ing patent through the current follow-up.
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ﬂuoroscopy times varied signiﬁcantly, mostly on the basis
of patient anatomy. High ﬂuoroscopy times were typically
a function of aortic angulation, type III arch, or prior
EVAR. For instance, patient 5 was administered 137 mL
of contrast material and had 187 minutes of ﬂuoroscopy;
but this patient had a type II TAAA with suprarenal angula-
tion of 81.6 degrees. Patient 7 had a type III arch, making
wire access from the axillary access challenging. The patient
also had a prior thoracic EVAR complicated by dissection
and suprarenal angulation of 109.2 degrees. Finally, patient
1 had 95 mL of contrast material administered with
137 minutes of ﬂuoroscopy time, but the patient also had a
type III arch with a type II TAAAwith signiﬁcant angulation.
The Viabahns are difﬁcult to visualize under ﬂuoros-
copy. Similar to the branch grafts, the renal arteries are
stented ﬁrst. For these, we access only one branch stent
at a time. Once the ﬁrst iCAST is deployed, the ﬁrst stent
blocks the branch stent for the other renal, making it easy
to cannulate. However, we prefer to have wire access in
both of the stents to the superior mesenteric artery and ce-
liac artery simultaneously so that we do not jail either vessel
when we deploy the bridging stent for the other. We can
verify that the wires are not in the same Viabahn by ﬁrst
obtaining wire access in the ﬁrst branch stent, then inﬂating
a balloon in the proximal limb, thus directing the next wire
into the other limb. This makes cannulation of the visceral
limb simple. Alternatively, intravascular ultrasound can be
used to verify wire access in each of the branch stents.
As pointed out in the Results section, two patients expe-
rienced dialysis-dependent renal failure. The ﬁrst patient had
previous infrarenal EVAR with suprarenal ﬁxation stent and
cuffwith suprarenalﬁxation.Thismade it so thatwewere un-
able to pass catheters or stents into either her right or left
renal arteries. The secondpatient had a forced expiratory vol-
ume in 1 second of 0.64 and an estimated glomerular ﬁltra-
tion rate of 32, an occluded right renal, and a stented left
renal for peripheral artery disease and renal insufﬁciency.
We were able to stent her left renal, but her renal function
never recovered. On follow-up CTA, once it was clear that
the patient was not going to regain function, the endo-
bypass was patent. At the time of diagnostic angiography,
no ﬂow in that renal was appreciated, and that renal was
able to be selected because of the previously placed stent.
Unfortunately, we did have one case of paraplegia. This
occurred in an elderly man who 6 years before underwent
thoracic aortic repair covering his left subclavian, requiring
a carotid-subclavian bypass, and 4 years before underwent
repair of a large infrarenal abdominal aortic aneurysm
with a suprarenally ﬁxed stent graft. On postoperative day
6, he developed a sudden and profound drop in blood
pressure and hemoglobin requiring aggressive resuscita-
tion. He was later found to have a signiﬁcant retroperito-
neal bleed complicated by clopidogrel and a platelet
count of less than 150. Because he was taking clopidogrel,
replacement of the spinal drain was not attempted. He has
since returned home and recovered from all insults except
the paraplegia. Appropriate protective measures againstcord ischemia should always be considered for these types
of repairs. We prefer to lower spinal pressure below
12 mm Hg after complete exclusion of the aneurysm. We
then increase mean arterial pressure to 85 to 90 mm Hg
and hold until the morning of postoperative day 2; then we
normalize the mean arterial pressure and clamp the spinal
drain. From here, we watch the patient’s neurologic status
closely during the next 4 to 6 hours. If it remains stable,
we remove the spinal drain and continue to watch for hypox-
ia, anemia, and hypotension. Of the 14 patients, 11 walked
out of the hospital and went home with an average length
of stay of 7.7 days. Patients are observed at 1 week, 1month,
6 months, and yearly for the rest of their lives. At follow-up,
the patients had noncontrasted CT scans and ultrasound. If
the creatinine concentration was below 1.4, they had a con-
trasted CTA. We looked for endoleaks, aneurysm sac
growth, stent graft migration, and limb occlusion. To date,
no graft migration or separation has been seen.
Two balloon-expandable covered stents were typically
used per visceral artery. Sometimes three can be used.
This allows the length of the overall bridge to be controlled
by the overlap of the covered stents. Whereas the balloon-
expandable stent grafts are relatively inﬂexible, we prefer
to use them with this application because of their stable
deployment. We also make sure to deploy the self-
expanding stent beyond the end of the balloon-expandable
stent to smooth the compliance transition to native artery.
To prevent separation, all graft overlaps were 5 cm for large
devices and 3 cm for branches, with all overlaps of the endo-
bypasses reinforced by the self-expanding stents.
All 14 patients had risk factors prohibitive for open
surgery. They were successfully treated with this total endo-
vascular approach to achieve a 30-day survival rate of 100%.
That 11 of the 14 patients (78.6%) were able to return to
their family environment directly after their hospital stay is a
measure of the quality of life that was preserved in these pa-
tients postoperatively. Again, we must emphasize that most of
the results for open surgery are in patients of low risk. We
believe this should be contrasted with the patients of the pre-
sent study who were all at high risk. Whereas long-term dura-
bility has not been proved for this device, we think that these
patients’ options are limited such that they clearly beneﬁt
from the less invasive procedure. Until industry develops a
standardized, off-the-shelf, multibranched stent graft that
can be used in urgent and emergency situations, a PAEG is
the only option we have for high-risk patients. This study
looked at only symptomatic and elective patients, so we
cannot draw any conclusions about outcomes for emergency
or ruptured patients. Because the proximal seal zone diameter
is the only measurement required for this multibranched sys-
tem, it has possibility to become the off-the-shelf system
needed to endovascularly treat this underserved patient pop-
ulation in the short time frame they require.
Because of our success to date, we are in the process of
obtaining a sponsor-investigator investigational device
exemption to further study the proposed system. The de-
vice evaluation strategy for this PAEG should allow us to
leverage substantial amounts of data from the master
JOURNAL OF VASCULAR SURGERY
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assemble this PAEG. This may help shorten the regulatory
path by minimizing the amount of testing required.
Limitations of this study include its retrospective nature
and lack of a control group. Because of the small number of
patients, we were not able to perform statistical analysis.
CONCLUSIONS
There are few medical maladies that have challenged
our specialty like the management of TAAAs. The layers
of complexity of this problem continue to grow as our
treatment options expand. Historically, only a small num-
ber of patients with this problem were deemed ﬁt enough
to undergo open repair. Only a handful of centers could
generate sufﬁciently reasonable and predictable outcomes
to justify considering such an extensive repair. With the
introduction of endovascular repair, we have opened the
door to treating more patients but have not necessarily
expanded the number of centers.
There is a need for a technique that empowers physi-
cians with a safe and simple way to treat these patients
closer to home while being able to maintain predictable
outcomes. The ideal endovascular system needs to be
modular so as to be an off-the-shelf system. Its conﬁgura-
tion needs to be nonanatomically based to widen the range
of anatomic conﬁgurations that can be treated. It must also
have “surgical bailouts” that allow the surgeon to be able
to stop the procedure at any point in the case while not
leaving the patient with compromised perfusion to any or-
gan system. We think that this approach, which makes use
of delayed distal seal, does this. It simpliﬁes case planning
by requiring only one measurement to be made in the
proximal seal zone; it can be used in an off-the-shelf way,
and it can accommodate a large variety of anatomies.
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procedure. Semin Vasc Surg 2012;25:153-60.Submitted Feb 7, 2014; accepted May 14, 2014.INVITED COMMENTARYMatthew J. Eagleton, MD, Cleveland, OhioThe authors present a unique endovascular solution for the
treatment of thoracoabdominal aortic aneurysms (TAAA)
involving alteration and assembly of commercial endografts bythe physician. The manuscript can be added to the growing
body of literature describing “creative techniques” to provide
endovascular treatment of TAAA, which include the use of
